Sustained reductions in TG and other lipids have been reported with plozasiran in the Phase 3 PALISADE trial, and in the MUIR and SHASTA-2 open label extension (OLE) study.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
